Psychedelic Science Newsletter
Issue #62November 2, 20267 studies

A single intranasal dose of a short-acting psychedelic cut treatment-resistant depression scores in a randomized trial

Psychedelic medicine's biggest logistical problem has always been the clock โ€” psilocybin sessions run six to eight hours, which is a hard sell for overstretched clinics.

A new randomized trial just tested whether a drug that compresses that window down to minutes can still move the needle on treatment-resistant depression.

A Brief Psychedelic Experience, One Dose, Published in JAMA ๐Ÿงช

  • Intranasal mebufotenin (5-MeO-DMT) โ€” a compound associated with short psychedelic experiences โ€” was tested in a randomized clinical trial against treatment-resistant depression, published in JAMA.
  • The appeal is structural: unlike psilocybin or LSD, which require hours of in-clinic monitoring, mebufotenin's psychedelic window is brief, potentially cutting the session footprint dramatically.
  • The study targets one of psychiatry's hardest problems โ€” patients who haven't responded to existing antidepressants โ€” with a single administration design.

Why it matters: If the efficacy signal holds, the logistics argument alone reshapes how psychedelic-assisted therapy could be deployed at scale.

๐Ÿ”— JAMA Journal Article ๐Ÿ—“๏ธ Oct 26

Key Findings

Psilocybin and Psychosis: 40 Years of Data, One Honest Takeaway ๐Ÿ„

  • A systematic review covering 1984โ€“2025 mapped the relationship between classical psychedelics โ€” LSD, psilocybin, ayahuasca, and mescaline โ€” and psychotic symptoms.
  • The review aimed to give clinicians and policymakers a framework for identifying who is most at risk, synthesizing evidence on prevalence, risk factors, and clinical characteristics across four decades of studies.
๐Ÿ’ก Risk exists, but the review is about identifying who carries it.

Mushrooms Invented Psilocybin Twice โ€” Independently ๐Ÿ”ฌ

  • A review of psilocybin's biosynthetic pathway found that mushrooms evolved the ability to produce the compound on two separate, independent occasions โ€” using genes and enzymes that are only distantly related or unrelated altogether.
  • The review also maps how psilocybin can be produced biocatalytically in lab settings, either in test tubes or in engineered organisms, which matters for pharmaceutical manufacturing.
๐Ÿ’ก Convergent evolution built the same psychedelic molecule twice, via different routes.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Microbiology and molecular biology reviews : MMBR Review ๐Ÿ—“๏ธ Oct 27

Psilocybin vs. Escitalopram: Does Sex Change the Outcome? โ™€โ™‚

  • A Bayesian secondary analysis of a psilocybin-versus-escitalopram trial examined whether treatment outcomes differed by sex โ€” a question rarely asked in psychedelic research, where females are often underrepresented.
  • Major depressive disorder already shows marked sex differences in prevalence and symptom patterns, making the gap in sex-stratified trial data a meaningful blind spot.
๐Ÿ’ก Sex-specific antidepressant outcomes remain underexamined, even in high-profile trials.
Top 20% journal ๐Ÿ”— Psychopharmacology Journal Article ๐Ÿ—“๏ธ Oct 26

A Ketamine Cousin With Fewer Side Effects โ€” In Mice โš—๏ธ

  • Researchers identified 3C-DCK, a rationally designed ketamine derivative, that produced rapid antidepressant-like effects in chronically stressed mice lasting up to 72 hours after a single 2 mg/kg dose โ€” longer than ketamine itself.
  • The mechanism runs through adenosine signaling in the prefrontal cortex rather than the pathways associated with ketamine's dissociative and abuse-related side effects. No hyperlocomotion or movement problems were observed in the animal model.
๐Ÿ’ก A ketamine derivative drove longer antidepressant effects via a cleaner signaling route, in mice.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Science China. Life sciences Journal Article ๐Ÿ—“๏ธ Oct 26

Ketamine in Adolescence Didn't Raise Addiction Risk Later โ€” In Rats ๐Ÿ€

  • Male and female rats given a therapeutic dose of ketamine (10 mg/kg daily for 7 days) during adolescence showed no increased voluntary alcohol consumption or cocaine reward behavior in adulthood compared to saline controls.
  • The dose was selected specifically because it produces antidepressant-like effects in adolescent rats, making it a relevant proxy for the clinical question of whether treating teenage depression with ketamine carries long-term addiction risk.
๐Ÿ’ก Adolescent therapeutic ketamine didn't raise later addiction risk in this rat study.
Top 20% journal ๐Ÿ”— Psychopharmacology Journal Article ๐Ÿ—“๏ธ Oct 26

Ketamine Reshapes Brain Entropy in Treatment-Resistant Depression ๐Ÿง 

  • Data from two neuroimaging clinical trials found that low-dose ketamine modulated brain entropy โ€” a measure of signal complexity โ€” in regions linked to mood regulation, reward, and motivation in patients with treatment-resistant depression.
  • Prior work had shown entropy reductions in those regions in depressed patients; this study examined whether ketamine shifts that pattern.
๐Ÿ’ก Ketamine's antidepressant effect may partly work by restoring brain signal complexity.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Journal of affective disorders Journal Article ๐Ÿ—“๏ธ Oct 26

Implications

The week's evidence pulls in one coherent direction: faster, cleaner, more targeted tools for depression that hasn't responded to standard treatment. The unresolved tension is translation โ€” adenosine derivatives and brain entropy findings come from animals and small imaging studies, while the mebufotenin trial's durability beyond a single dose remains an open question.

Studies in this issue

Primary sources used for this newsletter.

  1. The genes and enzymes involved in making psilocybin
    key findingMicrobiology and molecular biology reviews : MMBR2026-10-27PMID 42937360
  2. A ketamine-related drug may have stronger antidepressant effects through adenosine signaling
    key findingScience China. Life sciences2026-10-26PMID 42932044
  3. Psychedelics and psychosis: A review of recent studies from 1984 to 2025
    key findingJournal of psychopharmacology (Oxford, England)2026-10-27PMID 42937077
  4. Differences between men and women in responses to psilocybin or escitalopram
    key findingPsychopharmacology2026-10-26PMID 42931904
  5. Low-dose ketamine may change brain signal complexity in hard-to-treat depression
    key findingJournal of affective disorders2026-10-26PMID 42933579